Bay City Capital Overview

  • Investor Type
  • Venture Capital
  • Status
  • Active
  • Professionals
  • 10
Professionals
  • Investments
  • 169
  • Portfolio
  • 12
  • Exits
  • 109
Exits

Bay City Capital General Information

Description

Founded in 1997, Bay City Capital is a venture capital and private equity firm based in San Francisco, California. The firm seeks to invest in the life sciences industry, with a focus on investing in companies within the bio-pharmaceuticals, drug discovery, medical devices, nutrition, healthcare IT and medical diagnostics sectors. The firm specializes in seed, early-stage, mid and late-stage, mezzanine and turnaround investments.

Contact Information

Year Founded
1997
Investor Status
Actively Seeking New Investments
Primary Investor Type
Venture Capital
Other Investor Types
Mezzanine
PE/Buyout
Primary Office
  • 750 Battery Street
  • Suite 400
  • San Francisco, CA 94111
  • United States
+1 (415) 000-0000

Bay City Capital Investments (169)

Company Name Deal Date Deal Type Deal Size Industry Company Stage Lead Partner
Xilio Therapeutics 02-Mar-2020 Early Stage VC 00000 Biotechnology Pre-Clinical Trials
00000 01-Feb-2020 00000 00000 000.00 Biotechnology Clinical Trials - Phase 2 0000 00000000000 00
00000000 13-Nov-2018 00000 00000 0000 Biotechnology Generating Revenue/Not Profitable
00000000 000 20-Jul-2018 00000 00000 00000 Biotechnology Clinical Trials - General
00000 0000000000 02-Apr-2018 00000 00000 00000 Biotechnology Generating Revenue/Not Profitable 000000000 000000 00.0
000000 00000000000 16-Feb-2018 00000 00000 000.00 Drug Discovery Generating Revenue/Not Profitable 000000 0000000 00.0
00000 000000000000 13-Feb-2018 00000 00000 0000 Drug Discovery Generating Revenue/Not Profitable
000 00000000000 05-Jan-2018 00000 00000 0000 Drug Discovery Generating Revenue 000000000 000000 00.0
Oculis 04-Jan-2018 Later Stage VC 0000 Biotechnology Generating Revenue 000000 000000
Gritstone Oncology 07-Sep-2017 Early Stage VC 000.00 Biotechnology Generating Revenue/Not Profitable
You’re viewing 10 of 169 investments. Get the full list »
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Bay City Capital Exits (109)

Company Name Exit Date Exit Type Exit Size
Imara 12-Mar-2020 IPO 000.00
0000000 20-Feb-2020 000000000000000000 00000
000000000 00000000 31-Dec-2019 000000000000000000
00000 25-Sep-2019 000000000000000000
00000000 000 08-Feb-2019 000 00000
000000 10-Dec-2018 000 00 00000000
00000 0000000000 31-Oct-2018 000 0000
000000000 00000000 28-Sep-2018 000 00000
Kezar Life Sciences 21-Jun-2018 IPO 0000
Xeris Pharmaceuticals 21-Jun-2018 IPO 000.00
You’re viewing 10 of 109 exits. Get the full list »

Bay City Capital Fund Performance

Fund Name Vintage Size Dry Powder DPI RVPI TVPI IRR

This information is available in the PitchBook Platform. To explore Bay City Capital‘s full profile, request access.

Request a free trial

Bay City Capital Investments by Industry, Year, and Region

Investments by Industry

Investments by Year

Investments by Region

PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.

Request a free trial

Bay City Capital Team (40)

Name Title Deals Funds Boards Office
Susan Vuong Chief Financial Officer & Chief Compliance Officer San Francisco, CA
Frederick Craves Ph.D Founder & Managing Director 00 0 0 San Francisco, CA
Carl Goldfischer MD Managing Director 00 0 0 San Francisco, CA
David Beier JD Managing Director 0 San Francisco, CA
Dayton Misfeldt Managing Director 0 0 0 San Francisco, CA
You’re viewing 5 of 40 team members. Get the full list »